目的 探討醒腦靜注射液聯(lián)合依達(dá)拉奉注射液治療重型顱腦損傷的臨床療效。方法 選取2017年2月-2019年3月武漢科技大學(xué)附屬普仁醫(yī)院收治的73例重型顱腦損傷患者，將所有患者按照不同的治療方式分為對照組（36例）和治療組（37例）。對照組靜脈滴注依達(dá)拉奉注射液，30 mL依達(dá)拉奉注射液加入100 mL氯化鈉注射液內(nèi)，2次/d。治療組在對照組治療基礎(chǔ)上靜脈滴注醒腦靜注射液，20 mL/次，2次/d。兩組患者均連續(xù)治療2周。觀察兩組的臨床療效，比較兩組的平均血流速度（V_m）、收縮血流速度（V_s）水平、殘余血腫量、水腫范圍以及血清腦血紅蛋白水平變化。結(jié)果 治療后，對照組總有效率83.3%低于治療組總有效率94.6%（P<0.05）。經(jīng)治療后，兩組患者V_m、V_s水平均顯著升高（P<0.05），且治療組V_m、V_s提高程度優(yōu)于對照組（P<0.05）。經(jīng)治療后，兩組患者水腫范圍、殘余血腫量與治療前相比均降低（P<0.05），且治療組水腫范圍、殘余血腫量改善程度優(yōu)于對照組（P<0.05）。治療后，兩組血清腦血紅蛋白水平均顯著提高（P<0.05），且治療組血清腦血紅蛋白水平高于對照組（P<0.05）。結(jié)論 醒腦靜注射液聯(lián)合依達(dá)拉奉注射液治療重型顱腦損傷具有較好的療效，可提高患者V_m、V_s水平，降低水腫范圍和殘余血腫量，具有一定的臨床應(yīng)用推廣價值。

Objective To evaluate the efficacy of Xingnaojing Injection combined with Edaravone Injection in the treatment of severe craniocerebral injury. Methods Patients (73 cases) with severe craniocerebral injury in Wuhan Puren Hospital Affiliated to Wuhan University of Science and Technology from February 2017 to March 2019 were enrolled in this study. According to the difference treatment plan, patients were randomly divided into the control group (36 cases) and the treatment group (37 cases). Patients in the control group were iv administered with Edaravone Injection, 30 mL added into normal saline 100 mL, twice daily. Patients in the treatment group were iv administered with Xingnaojing Injection on the basis of the control group, 20 mL/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and V_m, V_s, residual hematoma volume, edema range, and cerebral hemoglobin in two groups were compared. Results After treatment, the total effective rate of the control group was 83.3%, which was lower than 94.6% of the treatment group (P<0.05). After treatment, the levels of V_m and V_s in two groups were significantly increased (P<0.05), and the improvement of V_m and V_s in the treatment group was better than that in the control group (P<0.05). After treatment, the edema scope and residual hematoma volume of two groups were decreased (P<0.05), and the improvement degree of the treatment group was better than that of the control group (P<0.05). After treatment, the serum levels of brain hemoglobin in two groups were significantly increased (P<0.05), and the serum level of brain hemoglobin in the treatment group was higher than that of the control group (P<0.05). Conclusion Xingnaojing Injection combined with Edaravone Injection has a significant therapeutic effect in treatment of severe craniocerebral injury, can improve the level of V_m and V_s, reduce the range of edemaand the amount of residual hematoma, which has a certain clinical application value.

R971